Gareth J Treharne

Sep 23, 2024 | acrjournals.onlinelibrary.wiley.com | Suz Jack Chan |Lisa K Stamp |Gareth J Treharne |Nicola Dalbeth

Supporting Information Filename Description acr25437-sup-0001-Disclosureform.docxWord 2007 document , 92.1 KB Disclosure Form acr25437-sup-0002-supinfo.docxWord 2007 document , 459.6 KB Supporting Information

Sep 22, 2024 | acrjournals.onlinelibrary.wiley.com | Suz Jack Chan |Lisa K Stamp |Gareth J Treharne |Nicola Dalbeth

INTRODUCTION Current treatment paradigms for managing rheumatoid arthritis (RA) aim to prevent joint damage and disability by frequently assessing disease activity and altering disease-modifying antirheumatic drug (DMARD) therapy to achieve either remission or low disease activity (LDA).1 Since the introduction of biologic DMARDs (bDMARDs), more people with RA are able to achieve a state of LDA or remission.2 Although bDMARDs are effective, their high cost and adverse event profile have led...